NCT07520006 2026-04-13
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Nurix Therapeutics, Inc.
Phase 1/2 Not yet recruiting
Nurix Therapeutics, Inc.
Canadian Cancer Trials Group
Eli Lilly and Company
Dana-Farber Cancer Institute
Eli Lilly and Company